CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead to acquire Interius BioTherapeutics for $350M, sees dilution
- Gilead Sciences’ Promising Phase 3 Study in Lung Cancer Treatment
- Gilead Sciences: Strong Market Position and Investor Confidence Justify Buy Rating
- Gilead price target raised to $135 from $120 at Bernstein
- Gilead upgraded to Outperform from Neutral at Daiwa